Skip to content

NORDBIOTIC™ IBS 10

10 scientifically tested probiotic strains for IBS

Discover how reduce IBS symptoms

Irritable bowel syndrome (IBS) poses a significant global health challenge, impacting millions

With a global prevalence of approximately 20%, IBS requires comprehensive and safe interventions that extend beyond conventional treatment. In developing the innovative multi-strain probiotic formulation NORDBIOTIC™ IBS 10, our goal is to provide scientifically validated, evidence-based dietary solutions.

By targeting the multifactorial nature of IBS, NORDBIOTIC™ IBS 10 supports key physiological functions and contributes to improving the quality of life of individuals living with IBS.

Irritable bowel syndrome (IBS) symptoms

  • sharp, cramping pains in the abdomen
  • relief from defecation or gas diarrhea (the diarrheal form of IBS)
  • constipation – in patients without diarrhea
  • abdominal distension, gases
  • nausea, vomiting
  • headaches
  • fatigue

Dysbiosis in IBS

Reducing the number of Lactobacillus and Bifidobacterium

Increase the numer of Streptococcus and Clostridium

Change in the ratio between Firmicutes and Bacteroidetes (decrease in the number of Bacteroidetes)

In patients with IBS, the risk of SIBO (increase in the number of bacteria in the small intestine) is about 5 times higher than in the control group (OR = 4.7, 95 CI: 3.1-7.2)

Probiotics in IBS

Numerous randomized controlled trials have demonstrated the effectiveness of probiotic supplementation as a supportive strategy in the management of IBS (currently around 40 randomized controlled trials).

Probiotics positively influence patients' perceived quality of life during IBS treatment.

The efficacy of probiotic supplementation has been further confirmed by recently published meta-analyses of randomized controlled trials.

NORDBIOTIC™ IBS 10 STUDY

The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study

Learn more
Dosage

Recommended Daily Dossage: 5 x 10⁹ CFU

Duration

8 weeks

Safety

Impeccably well-tolerated with no reported adverse events

Conclusion
NORDBIOTIC™ IBS 10, a multi-strain probiotic formulation administered at a dose of 5 billion CFU daily for 8 weeks, demonstrated statistically significant improvements compared with placebo. The formulation was well tolerated and safe, showing a significant positive effect on patient well-being and quality of life. These findings highlight the clear benefits of our multi-strain probiotic formulation for adults with IBS.
Key proven benefits
  • Statistically significant reduction in IBS symptom severity (IBS-SSS).
  • Improved quality of life.
  • Improved well-being and quality of life – 92% of patients in the NORDBIOTIC™ IBS 10 group showed significant improvement.
Tested strains
  • Lacticaseibacillus rhamnosus LR110 / 1,11 x 10⁹ cfu
  • Bifidobacterium lactis BI 040 / 0,835 x 10⁹ cfu
  • Bifidobacterium breve BB010 / 0,415 x 10⁹ cfu
  • Lacticaseibacillus paracasei LPC100 / 0,415 x 10⁹ cfu
  • Lactobacillus acidophilus LA120 / 0,415 x 10⁹ cfu
  • Lacticaseibacillus casei LR130 / 0,415 x 10⁹ cfu
  • Lactiplantibacillus plantarum LP140 / 0,415 x 10⁹ cfu
  • Streptococcus thermophilus ST250 / 0,415 x 10⁹ cfu
  • Bifidobacterium longum BL020 / 0,280 x 10⁹ cfu
  • Bifidobacterium bifidum BF030 / 0,280 x 10⁹ cfu

92% of patients in NORDBIOTIC™ IBS 10 group show significant improvement

IBS-Global Improvement Scale (IBS-GIS)

60% of patients in the NORDBIOTIC™ IBS 10 group classified their IBS as mild

IBS- Severity Scoring Scale (IBS-SSS)

52% of patients in NORDBIOTIC™ IBS 10 group show improvement

IBS- Severity Scoring Scale (IBS-SSS)

36% of patients in the NORDBIOTIC™ IBS 10 group reported symptom relief

IBS- Severity Scoring Scale (IBS-SSS)

Why do scientifically tested probiotics matter?

 

NORDBIOTIC™ IBS 10

Not-tested probiotics

Proven effectiveness

Safety and reliability

Strain specificity

Trust and transparency

This website contains information about the research and development activities of Nordic Biotic Sp. z o.o. relating to food products in the form of probiotic preparations. In particular, it is intended to describe and summarize the results of scientific studies organized by the company on such preparations. The activities of Nordic Biotic Sp. z o.o.:
  1. Do not relate to medicinal products, including the organization of clinical studies, research and development activities, manufacture, or offering of medicinal products or their components, including active pharmaceutical ingredients.
  2. Do not involve the manufacture or sale of food products to consumers.
This website is intended exclusively for professional food business operators, in particular manufacturers of food products, including food supplements, who are interested in the research and development activities of Nordic Biotic Sp. z o.o. and in applying the results of such activities in their own manufacturing or distribution operations.